Scientific Advisory Board
Gordon Mills M.D., Ph.D. - Chairman, Department of Molecular Therapeutics & Professor of Medicine and Immunology, The University of Texas M.D. Anderson Cancer Center
Background: Dr. Mills is the chair of the MD Anderson cancer center. He is a highly regarded expert in the field of cancer and lipid research. Dr. Mills is on the external advisory board of several cancer research centers including centers at Vanderbilt and Baylor as well as centers in Toronto and Seattle. Dr. Mills is also a consultant for a variety of lipid research companies including Echelon Pharmaceuticals and Cytovia Inc. Dr. Mills provides a broad knowledge of preclinical and clinical drug and antibody development in the lipid research field.
Edward Dennis, Ph.D.- Professor of Pharmacology, Chemistry and Biochemistry, School of Medicine, University of California, San Diego
Background: Dr. Dennis is considered an expert in the field of lipid research and inflammation with over 250 publications in this area. He is Editor-in-Chief of the top rated Journal of Lipid Research and has chaired numerous international symposiums on bioactive lipids, lipidomics, cancer and inflammation. He has held numerous consultant positions in large pharma including Lilly and Hoffman La-Roche and Board of Directors and SAB positions in biotech. Dr. Dennis provides expertise in the field of lipid research.
Joseph Witztum, M.D.- Professor of Medicine, Division of Endocrinology, School of Medicine, University of California, San Diego
Background: Dr. Witztum's research lab at UCSD focuses upon lipoprotein metabolism and mechanisms by which LDL contribute to atherogenesis at the level of the artery wall, oxidized LDL and prevention. His lab works on imaging of atherosclerosis using novel monoclonal antibodies to epitopes found in atherosclerosis lesions. Dr. Witztum is an expert in anti-lipid antibody development and angiogenesis.
Doug Grotjahn, Ph.D.- Professor of Chemistry, San Diego State University
Background: Dr. Grotjahn is an organic chemist with expertise in catalytic applications of organometallic compounds, hybrids between organic and inorganic materials. Dr. Grotjahn advises the Company in the development of lysolipid analogs.